News and Events
DAWN2™ Global Results MeetingNovember 2012
The initial results of the DAWN2™ study were reviewed by representatives of key international and national diabetes organisations, clinicians, researchers, people with diabetes and their family members on the 2nd and 3rd of November last year. These key stakeholders from all continents – who are committed to supporting the wider implementation of the study’s results – gathered in Copenhagen for a meeting hosted by the global partners of DAWN2™: the International Diabetes Federation (IDF), the International Alliance of Patients’ Organizations (IAPO), the Steno Diabetes Center and Novo Nordisk.
Members of the DAWN2™ International Publication Planning Committee (IPPC) presented the study’s initial results at the meeting, and workshops helped delegates to identify the most important messages from the study’s results and develop action plans for improving diabetes care in partnership with all relevant stakeholders.
A press release issued in December last year by Novo Nordisk and the study’s global partners highlighted some of the DAWN2™ study’s initial findings, focusing on the experiences of family members of people with diabetes and the lack of support available to them as caregivers.
These findings include the following:
- 63% are anxious about their loved one developing serious complications from the condition
- 66% are fearful that their loved one will experience hypoglycaemia – with potentially fatal
consequences - during the night
- 34% report that their loved one’s diabetes has a negative financial impact on their own life
- One in five have experienced their loved one being discriminated against and intolerance of
people with diabetes within their community
- Over one-third 37%) do not know how best to help their loved one manage his/her diabetes
- 75% had not attended a diabetes education programme, in spite of the fact that at least 70% of
diabetes healthcare professionals see the involvement of family members as a vital part of
good diabetes care
The remaining results are being analysed and prepared for inclusion in scientific publications, with the first publications containing the results scheduled for spring 2013. After their publication the DAWN2™ study results will be made available to the general public in each country involved in the study, as well as internationally.
DAWN2™ at EASD 2011September 2011
At the EASD conference in Lisbon, Portugal Novo Nordisk was proud to announce the launch of a the new and unique global study, DAWN2™. The study aims to gain a 360°perspective on life with diabetes. DAWN2™ will engage key stakeholders in finding new ways to enable people with diabetes to live full, healthy lives and be actively involved in managing their own health.
Dr. Mark Peyrot, an internationally recognized professor of sociology from the US who shared his views on the unique prospects of DAWN2™.